Aquestive Therapeutics (AQST) Stock Analysis & AI Equity Report
Aquestive Therapeutics (AQST) overview
Aquestive Therapeutics (AQST) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 44.5m and operating profit of USD -71.1m; the year-end share price was 6.46 USD and market capitalisation was USD 788m. Aquestive Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Aquestive Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Aquestive Therapeutics
Aquestive Therapeutics develops pharmaceutical products and drug delivery technologies, including oral film formulations and epinephrine prodrug candidates. It manufactures four licensed commercialized products marketed by licensees in the United States and elsewhere, and collaborates with pharmaceutical companies to develop and commercialize medicines using its technologies. Its pipeline includes candidates intended for severe allergic reactions and other conditions.
Generate the Aquestive Therapeutics report
Aquestive Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Aquestive Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Aquestive Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.